MedTrace Logo

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

NCT02956382 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-07-18

Study results available
· View outcomes & findings →

Summary

This is a phase I/II study in which patients will be enrolled in a standard 3+3 design. Once the maximum tolerated dose (MTD) is determined amongst patients with relapsed or refractory grade 1-3a follicular lymphoma, there will be a 17-patient phase II study.

Conditions

  • Refractory Follicular Lymphoma
  • Relapsed Follicular Lymphoma

Interventions

DRUG

Ibrutinib

Ibrutinib is dispensed as a capsule.

DRUG

Venetoclax

Venetoclax is dispensed as a tablet.

Sponsors & Collaborators

  • AbbVie

    collaborator INDUSTRY

  • Pharmacyclics LLC.

    collaborator INDUSTRY

  • Hackensack Meridian Health

    collaborator OTHER

  • Georgetown University

    lead OTHER

Principal Investigators

  • Chaitra Ujjani, MD · Seattle Cancer Care Alliance

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2023-05-23
Completion
2024-03-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02956382 on ClinicalTrials.gov